MCBRIDE PLC (MCB) — Investment Research Note

Executive summary

McBride is Europe's leading private-label and contract manufacturer of household and professional cleaning products (laundry, dishwash, surface cleaners, unit-dose, aerosols), operating 14 factories across Europe and Asia-Pacific 2025-09 final. The Group has executed a sharp recovery from a near-fatal 2022 input-cost crisis (adjusted operating loss of £24.5m in FY22) to three consecutive years at materially higher profitability (adjusted EBITA £66.1m in FY25, with H1 FY26 stable) on the back of three-month pricing terms, a focused divisional operating model, and consumer migration to private-label as cost-of-living pressures persist 2026-02 interim, 2025-09 final. The single most important point for valuation today is that the 12 June 2026 trading update flagged a 5–10% cut to FY26/FY27 EBITA consensus due to Middle East–driven input cost inflation — the resulting share-price drop (-14.6% on the day, currently 141.6p) appears to price in the cycle without giving credit to the immediately-accretive Eurotab acquisition or the £20m+ buyback running through a depressed share price.

Fair value estimate

Fair value range: 175p – 215p per share (implied market cap £299m – £367m at ~171m shares).

Methodology: blend of forward P/E (8–10x) and EV/EBITDA (5.5–6.5x) on FY27 estimates, plus modest credit for Eurotab synergies.

Key assumptions:

• FY27 adjusted EBITA: £63m–£67m (consensus £70.6m haircut by 5–10% per 12 June update) 2026-06 trading
• FY27 adjusted EPS: ~22–24p (post finance costs of ~£10m and effective tax ~30%) 2026-02 interim
• Eurotab adds c.€7–8m EBITDA pre-synergy, c.€12m at full synergy 2026-04 acquisition
• Net debt post-Eurotab: ~£155m (1.7x EBITDA), still inside covenants
• 8–10x P/E reflects below-average growth, cyclical margin profile, but supports the consumer-staples-end-of-spectrum quality and the demonstrated three-year run of stable mid-9% EBITDA margins

Vs. current market cap of £241.9m, midpoint fair value of ~195p (£333m) implies ~38% upside.

Sector context

Sector confirmed: Personal Care, Drug and Grocery Stores (consumer staples). McBride is below typical staples peers on margin (8–9% EBITDA vs. branded peers at 15–20%+) but is the European private-label leader by scale. Quality/growth/leverage profile is below large-cap staples (Unilever, Reckitt) and broadly in line with smaller private-label specialists. Relevant listed peers: Henkel, Reckitt Benckiser (as branded counterparties whose share they take), and Spectrum Brands; no perfect listed pure-play private-label peer in Europe.

Investment thesis

1. Sustained earnings reset already evidenced over five half-years. Three consecutive years of adjusted EBITA in the £60–66m range, with H1 FY26 in line with H1 FY25, validates that the 2022 trough was a working-capital/inflation shock, not a business-model failure. Net debt has fallen from £166m (FY23) to £105m (FY25), with the dividend reinstated and a £20m buyback running 2025-09 final, 2026-02 interim.

2. Eurotab acquisition is immediately EPS-accretive and tightens the Unit Dosing moat. Paying 5.2x EBITDA (3.1x post-synergy) for a tablet-format specialist with free capacity that solves McBride's own Unit Dosing capacity constraints. Funded from existing facilities, will keep net debt/EBITDA at ~1.6x 2026-04 acquisition.

3. Board signal value through buyback + EBT purchases. Directors explicitly stated the share price "fundamentally undervalues" the Group and committed to escalating buyback authorities (10% → 25%) if the discount persists; £12.9m returned in H1 FY26 alone via dividends, buyback and EBT funding 2025-11 AGM update, 2026-02 interim.

Key risks

1. Input-cost mismatch / pricing-recovery lag. The 12 June 2026 update is a fresh reminder: Middle East–driven petrochemical and energy inflation will hit Q4 FY26 and Q1 FY27 before the three-month pricing cycle catches up. Historical evidence (FY22) shows that severe spikes can wipe out a full year of profit before recovery 2026-06 trading, 2022-09 final.

2. Customer concentration risk in retail. Top ten customers are 53% of revenue 2025-09 final. Loss of one or two private-label contracts (as already seen in Italy and Powders historically) can move a division from profit to loss quickly.

3. Defined-benefit pension deficit £23.1m with profit-linked contributions. Conditional contributions up to £1.7m/year kick in above £30m adjusted operating profit, and £5.7m/year base contributions run to 2028. The Virgin Media/NTL ruling is a disclosed contingent liability 2026-02 interim.

Operating leverage

McBride is an asset-heavy industrial manufacturer with moderate, not high, operating leverage. Gross margin sits around 36–37% (H1 FY26: £173.4m/£475.2m) and adjusted EBITDA margin has plateaued at 8.8%–9.3% across the recovery period 2026-02 interim, 2025-09 final. Fixed-cost base includes 14 factories, central admin (£8–9m/yr), and the SAP S/4HANA programme. The clearest evidence of leverage: between FY22 (£678m revenue, -£24.5m EBITA) and FY25 (£927m, +£66.1m), a 37% revenue increase delivered a £90m profit swing — but most of that was margin recovery from pricing, not pure volume leverage. On the upside today, with Eurotab adding ~€65m revenue at ~12% EBITDA margin, a 10–20% organic revenue beat would more likely add ~30–50% to EBITA, not multiples. The Aerosols division (£2.5m personal-care expansion capex delivering > +500bps margin) is the best example of capacity-constrained operating leverage in the portfolio 2026-02 interim. Capacity utilisation in Unit Dosing is the bottleneck the Eurotab deal explicitly fixes 2026-04 acquisition.

Value-trap signals

• Trading update of 12 June 2026 itself: a fresh 5–10% downgrade is a recent miss, not yet absorbed
• Cyclical exposure to petrochemical feedstocks; FY22 demonstrated tail-risk
• Pension overhang and profit-linked contributions

These are signals of risk, not of structural decline. Volumes are growing, private-label share is at all-time highs, and the board is buying back stock. Not a value trap on current evidence.

Earnings vs. expectations

The pattern across the five-year window is: severe miss in FY22 (multiple profit warnings during inflation spike), then a sequence of in-line to modest beats through FY23–H1 FY26 (consistently "in line with analyst expectations" wording, with the April 2023 update flagging £5–10m ahead, July 2024 confirming "expected strong" performance) 2023-04 trading, 2024-07 trading, 2025-07 trading, 2026-01 trading. Then a 5–10% downgrade in June 2026 to both FY26 and FY27 consensus driven by Middle East cost shock 2026-06 trading. Pattern: solid record of meeting/modestly beating since the reset, broken by the most recent print.

Conviction

Conviction: 3 (moderate).

Anchors: (i) three-year track record of stable EBITDA in a £75–86m band gives a defensible earnings base; (ii) the company is in a sector with mature, transparent accounting and clear peer benchmarks; (iii) board's own actions (buyback at these prices, Eurotab deal commentary) signal management view of fair value broadly aligned with my estimate.

Caveats: (i) input-cost volatility means any point estimate has a wide range — the June 2026 cut shows how quickly the model can move; (ii) DCF terminal-value sensitivity is high for a low-growth, mid-single-digit-margin business.

Driver scoring

• AI beneficiary: 5. McBride is a fast-moving consumer-goods contract manufacturer with zero meaningful AI-receiver exposure. SAP S/4HANA spend benefits SAP, not McBride. The data and process improvements support productivity but no AI-driven revenue line.
• Operating leverage: 45. Moderate. Heavy fixed-asset base, but variable raw materials and logistics are c.55–60% of cost; incremental revenue earns near-average margin, not multiple. Modest spare capacity (now being supplemented by Eurotab) limits upside surprise to operating profit.
• Earnings surprise trend: 45. Three years of in-line performance broken by the June 2026 downgrade. Net "more in line than beat", with one fresh miss.
• Cyclicality: 55. Higher than typical staples — petrochemical feedstock exposure, energy intensity, exposure to consumer disposable income via private-label demand (counter-cyclical lift, but margin highly cyclical).
• Moat: 35. Scale in European private-label is meaningful but moat is execution, not structural — switching costs are real for retailers but retailers also dual-source. Tablet-format know-how (especially post-Eurotab) is the strongest single moat element.
• Leverage: 35. Net debt/EBITDA at 1.4x at H1 FY26, rising to ~1.7x post-Eurotab. RCF extended to 2029 with 0.5x cover ratio. Pension deficit £23m. Reasonable but not fortress.
• Earnings quality: 60. Cash conversion 109% in FY25, 58% in H1 FY26 (working-capital seasonal). Adjusted-to-statutory bridge is modest (exceptionals £4m in FY25, £2.4m H1 FY26). Audit clean post-FY23. Some adjusting items recurring (ERP, "growth options review").
• Management quality: 60. Capital-allocation discipline: dividend reset (cut then reinstated when leverage normalised), buyback at depressed prices, disciplined M&A at 3–5x EBITDA. CEO Chris Smith has led the recovery credibly.
• Growth momentum: 45. Revenue effectively flat in H1 FY26 (+0.8% reported, -2.1% constant currency). Volume growth modest (+0.4%). Eurotab adds inorganic step-up. Not accelerating, not declining.

overall_score: 380

Rationale: McBride is outside the AI-receiver thesis (the dominant ~35% weight) — there is no demonstrable AI revenue or moat. Valuation is genuinely cheap (P/E ~6–7x, fair value 30–40% above current price), which earns points on the "don't overpay" pillar, and downside protection is acceptable. But operating leverage is moderate-at-best, growth is mid-single-digit, and the AI angle is essentially zero. This is a fine value/recovery name with a fair price, but it does not capture the strategy's central thesis.